Pain News and Research

Latest Pain News and Research

Timely treatment with Berinert provides faster symptom relief for HAE patients

CSL Behring announced today that treatment with Berinert, C1 Esterase Inhibitor (Human) within six hours of the onset of an acute hereditary angioedema (HAE) attack provides faster symptom relief than later treatment, according to data presented at the 2012 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

7 Mar 2012

Shire to commence two Vyvanse and Concerta Phase 4 comparison trials for ADHD

As part of its continued commitment to ADHD research, Shire plc, the global specialty biopharmaceutical company, today announced it is initiating two Phase 4 clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta (methylphenidate HCl) Extended-Release Tablets.

7 Mar 2012

AcelRx initiates ARX-01 Phase 3 study for treatment of post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported dosing of the first patient in a Phase 3 study for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia system.

6 Mar 2012

Marriage boosts survival following coronary artery bypass surgery

Married adults who undergo heart surgery are more than three times as likely as single people who have the same surgery to survive the next three months, a new study finds.

6 Mar 2012

WLDI announces program for current subscribers to obtain ODG Certification

Work Loss Data Institute (WLDI), publisher of Official Disability Guidelines (ODG), the nationally recognized, multi-disciplinary standard for evidence-based medicine for medical treatment and return-to-work, is pleased to announce a program for current subscribers to obtain ODG Certification.

6 Mar 2012

Mayo Clinic experts available to discuss latest colorectal cancer research and treatment

March is National Colorectal Cancer Awareness Month. Colon cancer is one of the most common and deadly cancers, and also one of the most preventable. Mayo Clinic experts are available to discuss the latest in colorectal cancer research, detection and treatment.

6 Mar 2012

Scientists identify gene that causes adult-onset primary cervical dystonia

Researchers have identified a gene that causes adult-onset primary cervical dystonia, an often-painful condition in which patients' necks twist involuntarily.

5 Mar 2012

AMAG fourth quarter total revenues decrease to $14.9 million

AMAG Pharmaceuticals, Inc. a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2011. As of December 31, 2011, the company's cash, cash equivalents and investments totaled approximately $230 million.

5 Mar 2012

New depression treatment “safe and effective”

Stimulating the brain with a weak electrical current is a safe and effective treatment for depression and could have other surprise benefits for the body and mind, a major Australian study of transcranial Direct Current Stimulation (tDCS) has found.

5 Mar 2012

Medtronic launches MRI passive leads approved for full body MRI scans

Medtronic, Inc. today announced the receipt of CE Mark (Conformité Européenne) and launch of the CapSure Sense MRI SureScan® pacing leads, which are approved for use during Magnetic Resonance Imaging (MRI). Medtronic introduced the first MR-Conditional pacemaker system in the world in 2008 and in the U.S. in 2011.

From Medtronic 5 Mar 2012

Zalicus completes reformulated Z160 Phase 1 clinical trial for pain

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.

5 Mar 2012

ACADIA, Allergan extend drug discovery collaboration

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc..

5 Mar 2012

FDA clears UELS contactless breast cancer imaging tool

UE LifeSciences Inc. (UELS), a medical device manufacturer focused on providing novel breast cancer screening solutions, announced today that it has received market clearance from the U.S. Food and Drug Administration (FDA) for its NoTouch BreastScan™ device. NoTouch BreastScan™ is a contactless breast-imaging tool cleared by the FDA specifically for adjunctive diagnostic screening for the detection of breast cancer.

5 Mar 2012

Tips to assess when gambling could be leading to process addiction

Whether it's a March Madness office betting pool or sitting in the sports books in Las Vegas placing bets on the Masters Golf Tournament and opening week of Major League Baseball, the coming months are fraught with sporting events which lure millions of gamblers to place their bets.

5 Mar 2012

BioLineRx granted Israeli approval for BL-7040 Phase II clinical trial for IBD

BioLineRx a biopharmaceutical development company, announced today that it has received approval from the Israeli Ministry of Health for commencing a Phase II clinical trial of BL-7040, an orally available molecule for treating Inflammatory Bowel Disease (IBD).

5 Mar 2012

Concert, Fast Forward partner to advance new approach to treat spasticity and pain in MS

Concert Pharmaceuticals, Inc. and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced a new collaboration to fund the preclinical advancement of C-21191, a deuterium-modified subtype-selective GABAA modulator developed by Concert with the therapeutic potential of treating spasticity and pain in multiple sclerosis (MS).

5 Mar 2012

Exelixis initiates cabozantinib and abiraterone phase 1 combination trial in CRPC

Exelixis Inc. today announced the initiation of a phase 1 dose-finding trial of cabozantinib in combination with abiraterone in men with metastatic castration-resistant prostate cancer (CRPC) who have disease progression following treatment with up to two prior chemotherapy regimens.

5 Mar 2012

Lixiu, BIEL announce distribution agreement for RecoveryRx devices

BioElectronics Corporation., the maker of inexpensive, disposable drug-free topical pain and healing devices, today announced an agreement with Shanghai Lixiu Medical Devices Co., Ltd. – a subsidiary of Shanghai SuoKang Medical Implants Co., Ltd. -- to sell BIEL's RecoveryRx, chronic wound and surgical devices, throughout the People's Republic of China to licensed medical providers.

5 Mar 2012

Study: Bioavailability similar among four subcutaneous IgG preparations

Data presented by CSL Behring today suggest that the bioavailability of immunoglobulin G (IgG) therapies is consistent when patients with primary immunodeficiencies switch from one IgG product to another by the subcutaneous route.

5 Mar 2012

Dutch mobile euthanasia units stir controversy

Controversy has been stirred by a system of mobile euthanasia units that will travel around the country to respond to the wishes of sick people who wish to end their lives in the Netherlands.

4 Mar 2012